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Abstract
Microarray technology is a powerful tool able to measure RNA expression for
thousands of genes at once. Various studies have been published comparing com-
peting platforms with mixed results: some find agreement, others do not. As
the number of researchers starting to use microarrays and the number of cross-
platform meta-analysis studies rapidly increase, appropriate platform assessments
become more important.
Here we present results from a comparison study that offers important im-
provements over those previously described in the literature. In particular, we
notice that none of the previously published papers consider differences between
labs. For this paper, a consortium of ten labs from the Washington DC/Baltimore
(USA) area was formed to compare three heavily used platforms using identical
RNA samples: Appropriate statistical analysis demonstrates that relatively large
differences exist between labs using the same platform, but that the results from
the best performing labs agree rather well.
Hosted by The Berkeley Electronic Press
1 Introduction
Microarray technology has become an important tool in medical science and ba-
sic biology research. The number of publications based on microarray data this
year is well over 1000. A first time user will find many platform options and little
guidance on the most appropriate for their application. Various comparison stud-
ies have been published presenting contradictory results. Some find agreement
1, 2, 3, 4, 5, 6
, others do not 7, 8, 9, 10. In this paper we demonstrate that the disagree-
ment found by some studies may be due to disputable statistical analyses. In par-
ticular, none of these studies consider the lab to lab variability. This lab effect is
well known to exist and has been observed in all scientific fields11. For this reason
it is essential to assess the lab effect before drawing conclusions about platform
performances.
In this paper we describe a comparison study that permits an appropriate as-
sessment of the competing platforms. A consortium of ten labs from the Washing-
ton DC/Baltimore (USA) area was formed to compare three of the leading plat-
forms. Each lab was given identical RNA samples which were processed accord-
ing to what each lab considered best practice. Five of the labs used Affymetrix
GeneChips, three used two-color spotted cDNA arrays, and two used two-color
long oligo arrays. We describe features of our experiment that are necessary for
such studies to be informative and a set of simple assessment measures useful for
summarizing and interpreting the observed data. Some of these assessment mea-
sures are also useful for quantifying the level of agreement across technologies,
an important task given the advent of cross-platform meta-analysis studies 12, 13, 14.
Such meta-analysis add substantial value to experimental datasets collected for
one purpose, but that are later recognized as having value for another.
To decide among various strategies for measuring the same quantity one looks
to optimize accuracy and precision. Because in many situations precision can
be improved at the cost of accuracy, and vice-versa, one tries to find the strategy
providing the “best” balance. The definition of best will depend on the application.
Thus, it is important to consider precision and accuracy in the context of a realistic
applied problem. For the comparisons presented in all the cited publications the
most common application of microarray technology, screening for a few candidate
genes that appear to be differentially expressed among thousands of null genes
that are not, was mimicked. The candidate genes are typically validated with an
established technology such as RT-PCR. In such experiments, the measurement
of interest is relative expression across the samples being compared, which is
quantified with log fold change (the log provides symmetry between genes that are
1
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up and down regulated). A preferred strategy will better distinguish the log fold
change of differentially expressed genes from the log fold change of null genes. A
fundamental problem with many of the cited papers1, 8, 9, 5, 6 is that conclusions are
established on accuracy assessments based on a very small subset of the genes,
without considering precision in the context of the “real-life” application.
An appropriate comparison experiment in the context of detecting differen-
tially expressed genes, requires at least the following three features: 1) To appro-
priately assess precision we should have an a-priori expectation of no fold change
for most genes. 2) To appropriately assess accuracy, an a-priori expectation of
non-zero log fold change of a few genes is needed. 3) To be able to distinguish
between platform effect and lab effect, at least two labs should provide data from
each platform. We have designed the first platform comparison experiment that
includes all of these features. To incorporate feature 1) into our experiment each
lab hybridized the same RNA to two separate arrays, referred to as technical repli-
cates, which permitted us to measure the technical variation for each lab. Feature
2) can be accomplished by the use of spike-in experiments15. However, the devel-
opment of spike-in experiments is costly and arguably unrealistic in the context
of platform comparisons. We developed an alternative strategy based on mixtures
from four human cell lines, each deficient for a gene required for peroxisome bio-
genesis. Specifically, we created two samples for which we expect a few genes
to be differentially expressed. For four specific genes we have an a-priori ex-
pectation of fold changes: 2:1, 3:2, 2:3, and 1:2. We refer to these genes as the
altered genes. For each of these samples we created an exact copy, or technical
replicate, for a total of four samples. Exact copies of these four samples where
hybridized by the ten labs. Details are given in Section 4. The raw data from each
lab was then pre-processed to form two replicates of relative expression measure-
ments, log (base 2) fold change, comparing the two samples for each gene. These
were then summarized with our assessment measures, which were used to assess
performance and agreement.
2 Results
We quantified relative expression between our two samples with log (base 2) fold
change. For each lab we had technical replicates, thus we obtained two replicate
log fold change measurements for each gene. These measurements were then
summarized with the assessment measures and plots used to assess platform per-
fomance. Table 1 and Figure 1 show the assessment measures and plots, described
2
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Figure 1: A) Box-plot of the difference in log fold change between replicate mea-
surements from each of the 10 labs. B) Observed log fold change versus nominal
(from RT-PCR) log fold change for the four altered genes. The results for each
of the 10 labs are represented with colors for the different platorms, as in A), and
numbers for lab IDs assigned within each platforms. The solid line is the identity
function and reprensents perfect accuracy.
in detail in Section 2.1, for all ten labs. In general, better accuracy and precision
was achieved by the Affymetrix labs. However, overall, the best performing lab
was two-color oligo lab 2 (each lab was assigned an arbitrary identification num-
ber). Furthermore, two-color cDNA lab 1 outperformed most Affy oligo labs in
many categories. The worst performance was observed from two-color oligo lab
1. Notice the best and worst overall performance came from labs using the same
platform. This fact underscores the importance of considering the lab effect. In
general, we found lab had a larger effect on, for example, precision than platform
and that the results from the best performing labs agreed rather well. Detailed
results are described in the remainder of this Section.
2.1 Assessment Measures and Plots
To summarize precision we use two simple measures: correlation across replicate
log fold change measurements and standard deviation (SD) of the difference be-
tween replicate log (base 2) fold change measurements. The latter measure can
3
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Table 1: Assessment measures for the 10 labs.
Proportion of Agreement
Platform Lab ID Correlation SD Signal (SE) 25 50 100
Affy oligo 1 0.48 0.32 0.63 (0.19) 0.72 0.56 0.54
Affy oligo 2 0.76 0.17 0.29 (0.08) 0.80 0.70 0.70
Affy oligo 3 0.67 0.24 0.70 (0.14) 0.68 0.66 0.60
Affy oligo 4 0.79 0.15 0.53 (0.08) 0.80 0.70 0.65
Affy oligo 5 0.59 0.25 0.36 (0.09) 0.64 0.68 0.55
two-color cDNA 1 0.65 0.23 0.59 (0.13) 0.68 0.64 0.65
two-color cDNA 2 0.68 0.21 0.08 (0.15) 0.28 0.30 0.38
two-color cDNA 3 0.46 0.23 -0.08 (0.13) 0.72 0.68 0.50
two-color oligo 1 0.68 0.51 0.03 (0.16) 0.40 0.36 0.33
two-color oligo 2 0.90 0.10 0.87 (0.17) 0.44 0.72 0.81
be interpreted as the typical percentage increase in log-fold change when looking
at replicate data. For example, a platform with standard deviation value of 0.14
will typically produce measurements (which in theory should be equal) that are
10% [log
2
(0.14) = 1.10] different. These assessment measures can also be used
to quantify the similarity between measurements made by different platforms.
Throughout the paper we will refer to these two assessment measures as corre-
lation and SD (columns 3 and 4 in Table 1). Box-plots of the differences used
to compute the SD are summary plots that provide more information, such as the
size of the largest difference. Figure 1A shows a box-plot for each lab. Both Table
1 and Figure 1A demonstrate that precision is comparable across platforms. With
the exception of two-color oligo lab 1, all the labs performed similarly, and it is
clear that the lab effect is stronger than the platform effect. Notice in particular
that if we order the SD values for the Affy labs in increasing order of lab techni-
cian experience, the SDs are 0.32, 0.25, 0.24, 0.17, 0.14, i.e. the more experience
the more precise. A figure plotting SD against years of experience is given in the
supplemental materials.
To assess accuracy we regressed the observed log (base 2) fold changes of the
altered genes against nominal log (base 2) fold changes obtained using RT-PCR.
Ideally, if the nominal fold change doubles, so should the observed fold change.
Thus on the log
2
scale, observed fold change should be linear in nominal fold
change with a slope of 1. Throughout the paper we will refer to this assessment
measure as signal (column 5 of Table 1). Scatter-plots of the observed versus
nominal log fold changes are a graphical way to summarize the same informa-
4
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tion while providing more details. Figure 1B shows the scatter plot for all labs
with an identity line added to demonstrate perfect accuracy. All the labs appear
to give attenuated log fold change estimates which is consistent with previous
observations15. In general, the Affy labs appear to have better accuracy than the
two-color platforms, although the best signal measure is attained by two-color
oligo lab 2. However, most of the observed differences are not statistically signif-
icant.
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Figure 2: A) Scatter-plot of observed log fold change from two-color cDNA lab 1
and Affy oligo lab 4. Points inside red circle represent genes that do not appear to
be differentially expressed. Blue points are genes that appear to be differentially
expressed. B) CAT plot showing curves of log fold change agreement between
lab replicates for list sized ranging from 25 to 100. The different colors repre-
sent the different platforms. The different line types represent the different labs
within each platform, thus each lab is represented by a unique color/line type pair.
The yellow strip represents critical values for rejecting the null hypothesis of no
agreement at the 0.001 level.
Our final assessment measure/plot is particularly useful for summarizing across
5
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technology agreement. In most experiments, we expect only some genes to be dif-
ferentially expressed, which attenuates correlations across technologies toward 0.
To see this, in Figure 2A we show a scatter-plot of the log fold changes obtained
for the best performing Affy oligo and two-color cDNA labs. Notice that about
95% of genes are within the blue circle where there appears to be no correlation.
These genes have fold-changes close to 0 and are probably not differentially ex-
pressed. Because we are measuring 0 log fold change plus random measurement
error for these genes, one does not expect across platform measurements to be
correlated. However, for the few genes outside the blue circle, which are likely
to be differentially expressed, there is good agreement. In practice we typically
screen a small subset of genes that appear to be differentially expressed. There-
fore, it is more important to assess agreement for genes that are likely to pass this
screen. are more important for this subset. To account for this fact we introduce
a new descriptive plot: the correspondence at the top (CAT) plot. To create the
CAT plot we rank genes by log fold change using two different measurements.
We then create lists of candidate genes for a range of list sizes. CAT curves show
the proportion of genes in common plotted against the size of the lists. Figure 2B
shows an example of CAT curves created by comparing lists generated by replicate
measurements from each lab. This plot shows, for example, that the agreement of
lists of the top 100 genes created from replicate fold-change measurements ranged
from 33% to 81% percent. For the CAT plots used in this study, we stop at a list
size of 100 because we do not expect more than 100 genes to be differentially
expressed, thus correspondence of larger lists are not of interest. As assessment
measures, we reported the value of these curves for list sizes 25, 50, and 100. We
will refer to these assessment measures as the Proportion of Agreement (columns
6, 7, and 8 in Table 1). Figure 2B also shows a yellow band representing critical
values, at the 0.001 level, against the null hypothesis of no agreement at all.
We used CAT plots to assess across platform agreement. Figure 3 shows CAT
curves where the agreement of the results from all labs are compared to the best
performing affy oligo lab (Figure 3A), the best performing two-color cDNA lab
(Figure 3B), and the best performing two-color oligo lab (Figure 3C). Figure 3
demonstrates that the Affy oligo labs are consistently similar to the best perform-
ing labs. Figure 3 also demonstrates that, apart from 2 labs, there appears to be
good agreement regardless of platform. For example, the agreement of Affy oligo
lab 4 with the four other Affy labs was 52%, 58%, 52%, and 60%, and with the
best performing two-color lab the agreement was 42%. Notice that the agreement
of the replicate measurements from Affy oligo lab 4 was 65%. In Figure 3 we
also see that the agreement of Affy oligo labs 1, 2, 3, and 5 with Affy oligo lab
6
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Figure 3: A) CAT plots with curves for each lab compared to the best performing
Affy oligo lab. The line types represent the different labs as in Figure 2. The
different color represent the different platforms. The black curve is the CAT curve
comparing the reference lab to itself. B) As A) but for the best performing two-
color cDNA lab. C) As A) but for the best performing two-color oligo lab.
4 is almost the same as the agreement of lab 4 with itself (comparing replicates).
The same is not true for the other technologies. This suggest that the Affymetrix
platform is by far the most consistent across labs. The supplemental material pro-
vides tables, showing all pairwise correlations and agreement proportions (in a list
of size 100) between the different labs, that support this result.
Throughout the paper and supplemental material we do not discuss the statisti-
cal significance of differences observed in the precision measures. This is because
these are based on thousands of data points and any difference shown in our tables
is statistically significant. The measure of accuracy is based on only 8 data points,
thus we include a measure of uncertainty in Table 1. Although the accuracy results
are not nearly as reliable as the precision results, the across platform CAT plots
provide a measure of relative accuracy based on enough data points to provide
reliable conclusions.
2.2 Pre-processing
In all microarray technologies a fair amount of further pre-processing occurs fol-
lowing image processing. Background corrections and normalization are typi-
cal steps. Various groups have shown that these steps can have a significant im-
pact on downstream analysis15, 16. Most array manufacturers provide analytic pre-
7
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processing software requiring very little input from the user. We found that within
and across platform performance can be greatly improved by the use of alternative
pre-processing algorithms.
2.3 Annotation
Unigene Locuslink
Refseq 9288
876
109
21
109
6
7021
4853
Figure 4: For each mapping (UNIGENE, LO-
CUSLINK, and REFSEQ) we obtain a differ-
ent set of genes that have identifiers in each
platform. This Venn diagram shows the agree-
ment between these three different lists.
For our analysis, probe level
data from Affymetrix oligo ar-
rays were pre-processed with
the robust multi-array analy-
sis (RMA)15. Print-tip nor-
malization with no background
correction was used to pre-
process probe level data from the
two-color technologies16. Be-
cause algorithms implementing
these methodologies are avail-
able from the Bioconductor project17,
we will refer to them as the
Bioconductor procedures. We
compared the results obtained
with this approach to those ob-
tained with what we consider
to be the default approaches:
Affymetrix’s MAS 5.0 algo-
rithms for Affymetrix oligo ar-
rays and median adjustment nor-
malization with background cor-
rection for the two-color tech-
nologies. Although in general the default procedures had slightly better accuracy
(not statistically significant), the gains in precision given by the Bioconductor
procedures were dramatic. For example, the SD assessment for Affy oligo lab 4
improved from 0.46 to 0.15. Furthermore, the agreement across technologies was
much improved. For example the correlation between Affy oligo lab 4 and two-
color cDNA lab 1 improved from 0.13 to 0.50. More detailed results are available
in the supplemental material. Because of the great improvement provided by the
Bioconductor procedures, we use them for all the results presented in this paper.
Each platform assigns a unique identifier to each of its features. However,
8
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these identifiers do not match across platforms. To match features across plat-
forms we use mappings matching features to genomic entities that are available
from various public data-bases. Resourcerer18 provides mappings linking features
to UNIGENE, LOCUSLINK, and REFSEQ for all the platforms used by the labs
participating in our experiment. Resourcerer also provides its own annotation
called EGO. Unfortunately, none of these mappings are one to one: Not all the
features in the arrays are annotated and some are annotated with more than one
genomic identifier. Therefore, given a particular annotation only a subset of the
array features will have an entry for each platform. Furthermore, these subsets
differ depending on which annotation one uses. Figure 4 shows a Venn diagram
representing the agreement between these subsets for UNIGENE, LOCUSLINK
and REFSEQ.
The annotation used to match had an effect on the across platform agreement.
For example, the correlation between measurements from Affy oligo lab 4 and
two-color cDNA lab 1 were 0.39 to 0.44 when using UNIGENE and EGO re-
spectively. More detailed results are available from the supplemental material.
We found that using the intersection of all four annotation mappings provided the
best agreement. All the analyses in this paper used the subset of genes obtained
from this intersection.
3 Discussion
We defined a series of assessment measures and plots used to compare three lead-
ing microarray platforms. These were justified by questions to assess agreement
for subsets of gene that are likely to pass this screenof to assess agreement for
subsets of gene that are likely to pass this screenbiological to assess agreement
for subsets of gene that are likely to pass this screeninterest and have practical in-
terpretations. The signal measure represents the expected log (base 2) fold change
of a gene that should be differentially expressed with nominal fold change of two
and the SD measure gives us the expected log (base 2) fold change of a null gene.
This combination gives us a clear idea of the signal to noise ratio. For exam-
ple, perfect accuracy, signal=1, with lack of precision, say SD=1, is not useful in
practice because distinguishing true positives, with large fold changes, from the
large number of false positives reaching fold changes greater than two would be
impossible. Notice that with SD=1 we would expect about 30% of the null genes
to have fold changes greater than 2. Similarly, perfect precision, SD=0, combined
with no ability to detect signal, signal=0, is even less useful since all fold changes,
9
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regardless of true biological signal, would be identical.
Our assessment measures and plots demonstrated that, in general, the Affymetrix
platform performed better than the two-color counterparts. However, we illus-
trated that labs using any of the two-color technologies can perform as well or
better than the best performing Affymetrix lab. The main difference was that the
Affymetrix platform was less susceptible to the lab effect. However, it is im-
portant to keep in mind that Affymetrix GeneChip arrays are substantially more
expensive than the alternatives.
We also demonstrated that relatively good agreement is achieved between the
Affymetrix labs and the best performing two-color labs. These results contradict
some previously published papers that find disagreement across platforms7, 8, 9, 10.
The conclusion reached by these studies are likely due to three misconceptions.
The first misconception is that absolute measurements of expression can be used to
assess across platforms. Notice that both studies using absolute measures found
disagreement7, 10. Results established on absolute measures are misleading be-
cause they are adversely affected by platform-dependent-probe-effects which can
be removed by considering relative measurements of expression instead. The sta-
tistical model used to motivate our assessment measures, described in Section 4,
can be used to demonstrate this point (see Section 4 for more details). Notice that
in all studies interested in differential expression, relative expression is the quan-
tity of interest, thus this type of measurement is always available. The second mis-
conception is that pre-processing has no significant effect on final results. With
one exception4 all previous studies used the default algorithms which have been
shown to be inferior to alternatives developed by the academic community16, 15.
Finally, the third misconception is that platform performance is not affected by
lab. The the existence of the sizeable lab effect was ignored in all previously
published comparison studies. This permits the possibility that studies using, for
example, an experienced technicians may find agreement and studies using a less
experienced technicians may find disagreement.
Although we found relatively good across platform agreement it is quite far
from being perfect. In Figure 2A we see that for many of the genes that are dif-
ferentially expressed there is agreement. However, there is a small group of genes
that had relatively large fold changes for one technology but not for the other. No-
tice in particular the group of points with large negative vertical scale values and
almost 0 horizontal scale values. In a recent report19 (included as supplemental
material) it was found that “in the small number of cases where there were dis-
crepancies in the microarray profiles, qRT-PCR generally failed to confirm either
result, suggesting that sequence-specific effects may make expression estimates
10
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difficult for any technique.” We conjecture that some genes are not correctly mea-
sured, not because the technologies are not performing adequately, but because
transcript information and annotation can still be improved.
Our results provide a useful assessment of three leading technologies, it also
demonstrates the need for continued cross-platform comparisons. We hope that
our study serves as a starting point for larger, more comprehensive comparisons.
More importantly, we expect our study to motivate the creation of some standards
that can be used to assess performance of microarray labs. We believe this is
essential for the success of microarray technology as a general measurement tool.
4 Methods
4.1 Sample Preparation
Each lab was given two identical aliquots from each of two different samples
containing variable amounts of four individual PEX mutant cell lines. We will
refer to the two large pooled samples as A and B respectively and to the aliquots
as A1 and A2 or B1 and B2. For this experiment A1 and A2 are identical to each
other while and B1 and B2 are also identical to each other but different from A1
and A2. RNA samples were provided in duplicate for the performance of technical
replicate labeling and hybridization at each expert lab. The four samples will be
denoted with A1, A2, B1, and B2.
RNA samples A and B were actually mixtures of four human cell lines, each
deficient for a gene required for peroxisome biogenesis. The cell lines were
PBD002, deficient for PEX120; PBD106, deficient for PEX621; PBD072, deficient
for PEX722; and PBD006, deficient for PEX1223. Nonsense mutations identified
in the four cell lines used in this analysis are predicted to dramatically reduce
mRNA levels for each gene through nonsense mediated RNA decay. The four
human skin fibroblast cell lines had been previously transformed with SV40 large
tumor antigen (T antigen) and have variable levels of aneuploidy. Master solu-
tions of A and B total RNA at 1.3µg/µl were generated by mixing individual
RNA preparations obtained from the 4 initial cell lines. The RNA was isolated ac-
cording to manufacturer’s instructions for TRIZOL (Invitrogen, Carlsbad CA) and
was subsequently ”cleaned up” using RNeasy (Qiagen. Valencia CA) . Sample A
was a mixture composed of 1/2 PBD002, 2/5 PBD106, and 1/10 PBD072 and
sample B was a mixture of 1/2 PBD106, 2/5 PBD072, and 1/10 PBD006. This
mixture strategy was designed as though the contribution of mRNA for a given
11
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PEX gene to sample A or B from a cell line carrying a mutation in that PEX gene
was negligible and that mutations in one of these genes does not affect expression
on any of the other three. Under this assumption, the expected ratios for the four
genes are: 2:1, 3:2, 2:3 and 1:2 for PEX1, PEX6, PEX7, and PEX12 respectively.
RNA integrity was verified by size distribution on gel electrophoresis, as well as
cDNA synthesis efficiency (yield and size) by one of the participating labs. The
samples were then aliquoted and distributed. The actual fold changes generated
by mixing will deviate from ideal for at least two reasons. First, mRNA for the
test PEX genes in mutant cells will not be precisely zero, although the level is
expected to be low. Furthermore, aneuploidy in the SV40-transformed cells can
contribute noise due to alterations in the amount of total RNA/average gene copy.
During the RNA preparation step, sib cultures from each cell line were analyzed
for karyotype. As it is common in such lines, aneuploid states were noted in each.
To obtain a realistic expectation of fold changes we used RT-PCR as described in
Section 4.2. The resulting fold-changes were 1.26, 1.50, 1/1.04, and 1/1.04 for
PEX1, PEX6, PEX7, and PEX12 respectively.
4.2 RT-PCR
Real-time polymerase chain reaction (real-time RT-PCR) confirmation studies
were done, for the four altered (PEX) genes, using total RNA of the same RNA
population used for the microarray study. Fluorogenic LUXTM primers (Invit-
rogen Life Technologies, Carlsbad, CA) were used to validate relative changes
in mRNA levels by multiplex RT-PCR, using an ABI Prism 7700 Sequence De-
tection System (Applied Biosystems, Foster City, CA). To remove genomic DNA
contamination, total RNA was treated with DNase I (Invitrogen Life Technolo-
gies, Carlsbad, CA) for 15 minutes at room temperature prior to cDNA synthe-
sis using the SuperScriptTM First-Strand Synthesis System for RT-PCR (Invitro-
gen Life Technologies, Carlsbad, CA). First strand cDNA was synthesized from
1µg of total RNA. Multiplex PCR reactions were performed in triplicate using
Platinum R© Quantitative PCR SuperMix-UDG and ROX reference dye (Invitro-
gen Life Technologies, Carlsbad, CA). Reactions were performed in 25 µl reaction
volume under the following conditions: 50◦C for 2 minutes, 95◦C for 2 minutes,
and 45 cycles of 95◦, 15 seconds, 55◦C, 30 seconds, 72◦C, 30 seconds. Results
were analyzed by the comparative Ct method (User Bulletin Number 2, ABI Prism
Sequence Detector 7700, P/N 4303859). The resulting fold changes are reported
in the previous Section and in Table 6 of the supplemental material.
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4.3 Microarray Hybridization
Each participating lab used their standard operating procedure to label, hybridize
and scan the samples provided. For Affymetrix labs, each sample was analyzed on
a separate HGU133A GeneChip. Two-color cDNA labs 1 and 2 used the Human
20K clone set from Research Genetics to create spotted arrays, and lab 3 used
custom spotted arrays containing 32,448 elements. The two-color oligo labs both
used Human Genome Oligo Set Version 2.0. Each of the two-color labs adopted a
co-hybridization and dye-swap scheme of their choice. Details about experimental
design and hybridization procedures for each lab are given in the supplemental
material.
4.4 Data Analysis
The assessment measures and Figures are motivated by a simple statistical model.
This model also motivates the use of relative, as opposed to absolute, measure-
ments of expression. A general model that describes the data well is
Yi,j,k = θi + φi,j + εi,j,k, (1)
where Yijk represents measurement k of log scale expression on gene i by plat-
form j. Here, θ represents absolute gene expression in the log-scale. The platform
specific probe or spot effect is denoted with φij . Measurement error is represented
with ε. Similar models have been described by various statistical groups16, 24, 25.
To illustrate how an incorrect statistical assessment can lead to an incorrect con-
clusion and to motivate appropriate statistical assessments we will consider each
of the effects in model (1) to be random. We will assume that they are mutually
independent with variances σ2θ , σ2φ, and σ2ε for the expression level, probe effect
and the measurement error respectively.
Many researchers have observed that the probe effect variance σ2φ is large26. In
fact, for Affymetrix arrays it appears there is more variation due to probe effects
than to different expression levels, i.e. σ2φ > σ2θ . This fact will result in large
correlations when comparing measurements from the same technology. However,
these high correlations are not to be interpreted as a positive aspect as they are
driven by the probe effects. To see this notice that within platform correlation is
given by:
corr(Yi,j,1, Yi,j,2) =
σ2θ + σ
2
φ
σ2θ + σ
2
φ + σ
2
ε
. (2)
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Table 2: Correlation and SD measures computed for absolute and relative mea-
surements of expression. Affy oligo lab 4 and two-color cDNA lab 1 are used for
this comparison.
Correlation SD
Absolute Relative Absolute Relative
Affy oligo versus Affy oligo 0.98 0.79 0.16 0.15
two-color cDNA versus two-color cDNA 0.91 0.65 0.29 0.23
Affy oligo versus two-color cDNA 0.40 0.44 0.91 0.25
This correlation is typically close to 1, but only because σ2φ is usually much larger
than σ2θ and σ2ε . Empirical results confirm this, see Table 2. If we compare across
platforms the correlation will not be as large, but only because the probe effect
is not common to the two platforms, for example Affymetrix probes are quite
different from the typical spot on a two-color cDNA array, and therefore does not
affect the correlation. In the across platform case, the correlation is given by:
corr(Yi,j,1, Yi,j,2) =
σ2θ
σ2θ + σ
2
φ + σ
2
ε
. (3)
Notice that the large σ2φ term is no longer in the numerator. A smaller correlation
is observed empirically, see Table 2.
A simple solution to the probe effect problem is to consider relative expres-
sion instead of absolute expression. Most experiments compare between different
samples, for example treatment versus control, diseased versus healthy, etc... thus
in general this type of measure is readily available.
Following model (1), we define the observed relative expression between sam-
ples A and B as
Mi,j,k = Y
A
i,j,k − Y
B
i,j,k = di + bi,j + δi,j (4)
with Y Ai,j,1 and Y Bi,j,k the absolute log-scale expression measure for samples A and
B respectively. Because the Y s are log scale measurements the difference M is
simply the log ratio of the absolute expression levels. The advantage of using this
quantity is that, in theory, the platform dependent probe effect is canceled out.
Here di represents the true amount of differential expression (log fold change),
and δi,j = εi,j,1 − εi,j,2 represents measurement error. In practice, the probe-
effect is not removed completely and thus we include the bi,j term to represent a
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platform-dependent bias. As before the within platform correlations are given by:
cor(Mi,j,1,Mi,j,2) =
σ2d + σ
2
b
σ2d + σ
2
b + σ
2
δ
(5)
and the across lab correlations by
cor(Mi,1,k, Yi,2,k) =
σ2d
σ2d + σ
2
b + σ
2
δ
. (6)
The correlation of the relative expression measurements can be seen in Table
2. Notice that the within platform correlations are substantially smaller and the
across lab correlation is a bit larger. In theory bi,j should be 0, but given the dif-
ferent ways transcripts are defined and the arrays constructed it is no surprise that
there is some positive variance σ2b which explains why the correlations in column
2 of Table 2 are not all the same. However, the data confirms that σ2b is much
smaller than σ2φ.
The above model calculations demonstrate that results based on absolute ex-
pression measurements are misleading because they are adversely affected by the
platform specific probe effect. We propose that only assessments based on rela-
tive expression are useful. All the results presented in this paper deal with relative
expression M as defined by equation (4).
The code and data necessary to reproduce the results presented in this pa-
per are available from http://www.biostat.jhsph.edu/˜ririzarr/
techcomp.
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